RESEARCH TRIANGLE PARK, N.C. – June 23, 2011 – Quintiles, a leading global biopharmaceutical services company, today announced that it has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Asia Awards 2011. Presented at the World Vaccine Congress Asia – currently under way in Singapore – the awards recognize and celebrate the leaders, innovators and pioneers in the Asian vaccines industry.
“I am proud that Quintiles’ vaccines team has received this well-deserved recognition,” said Bhavani Sivalingam, Asia Alliances at Quintiles. “This especially recognizes our excellence in helping customers develop vaccines for malaria, Japanese encephalitis, dengue and other deadly diseases, as part of Quintiles’ efforts to improve health care globally.”
Since 2007, Quintiles has provided clinical services for more than 150 vaccine trials, involving almost 300,000 patients worldwide. With a track record of more than 17 years running projects in Asia, Quintiles’ local vaccine trial involvement is extensive. Experience with vaccines in Asia spans 39 studies across 258 sites, involving more than 31,000 patients between 2008 and the end of 2010 alone. Studies covering influenza, HIV, Japanese encephalitis, dengue fever, hepatitis B, measles and meningitis have been carried out in Southeast Asia, India, Bangladesh, Australia and New Zealand.
Quintiles was recently named a preferred provider to a consortium of 14 global health Product Development Partnerships (PDPs), which leverage the combined size of their pipelines to ensure the most cost effective use of their research and development dollars. PDPs are not-for-profit entities formed to advance global health and the health of the world’s poorest countries through the discovery, development and delivery of new effective and affordable medicines for the most neglected diseases in the world. Consortium members are funded, in part, by the Bill and Melinda Gates Foundation. These 14 PDPs anticipate funding 128 (phase I-IV) clinical trials over the next two years (2011-2013).
About QuintilesQuintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.